REGN vs INCY — Key Metrics
| Metric | REGN (REGENERON PHARMACEUTICALS INC) | INCY (INCYTE CORP) |
|---|---|---|
| Price | 758.27 | 121.35 |
| Market Cap | 78.07 Billion | 24.6 Billion |
| P/E (TTM) | 18.08 | 14.94 |
| P/B (Quarterly) | 2.397 | 4.151 |
| P/S (TTM) | 5.03 | 4.23 |
| Net Profit Margin (TTM) | 27.9 | 27.7 |
| Gross Margin (TTM) | 84.9 | 92.6 |
| ROE (TTM) | 13.8 | 29.6 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
REGN · REGENERON PHARMACEUTICALS INC
Greatly Outperform
INCY · INCYTE CORP
Greatly Outperform
Recommendation Summary
Both stocks are projected to significantly outperform the market over the next year. If you have to make a choice, Upfront Recommendation: INCY.
Financial Metrics
Prices delayed ~15 min
| REGN | Metrics | INCY |
|---|---|---|
| $758.27 | Price | $121.35 |
| — | Market Capitalization | — |
| 18.08 | Price to Earnings Ratio | 14.94 |
| 5.03 | Price to Sales | 4.23 |
| 20.76 | Price to FCF Ratio | 12.81 |
| 5.92 | Price to Gross Profit | 4.56 |
| 12.44 | Price to R&D | 11.44 |
| 4.23 | Price to Current Assets | 4.08 |